Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Cost effects of restricting cost-effective therapy.

Bloom BS, Jacobs J.

Med Care. 1985 Jul;23(7):872-80.

PMID:
3925258
2.

Formulary management of antiulcer drugs: economic considerations.

Tucker PP, Nash DB.

Pharmacoeconomics. 1994 Apr;5(4):313-34. Review.

PMID:
10147240
3.

Medicaid formularies: a critical review of the literature.

Jang R.

J Pharm Mark Manage. 1988 Spring;2(3):39-61. Review.

PMID:
10302873
4.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
5.

Economic assessment of peptic ulcer disease treatments.

Jensen DM.

Scand J Gastroenterol Suppl. 1988;146:214-24. Review.

PMID:
2906466
6.
7.

Pharmaco-economic considerations in the long-term management of peptic ulcer disease.

Ruszniewski P.

Aliment Pharmacol Ther. 1993;7 Suppl 2:41-8. Review.

PMID:
8103375
8.

Ranitidine: a pharmacoeconomic evaluation of its use in acid-related disorders.

Frampton JE, McTavish D.

Pharmacoeconomics. 1994 Jul;6(1):57-89. Review.

PMID:
10147354
9.

Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis.

Ford AC, Delaney BC, Forman D, Moayyedi P.

Am J Gastroenterol. 2004 Sep;99(9):1833-55. Review.

PMID:
15330927
10.

Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis.

Barradell LB, McTavish D.

Pharmacoeconomics. 1993 Jun;3(6):482-510. Review.

PMID:
10146883
11.

[Treatment of peptic ulcer: an economics perspective].

Venables CW.

Rev Clin Esp. 1987 Nov;181(8):461-7. Review. Spanish. No abstract available.

PMID:
3326070

Supplemental Content

Support Center